Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today. The three-year trial was conducted among 650 adolescents in Tanzania, a nation with high rates of TB infection, and showed that the vaccine was safe and induced immune responses against the disease.
